Previous 10 | Next 10 |
LONDON, May 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases today announced that data from the Phase 2 “ASTRAEUS” trial of alvelestat fo...
2023-05-08 13:15:58 ET The U.K.-based biotech Mereo BioPharma ( NASDAQ: MREO ) announced Monday that the company regained compliance with the minimum bid price requirement under the Nasdaq Listing Rules. Mereo ( MREO ) said that the Nasdaq Stock Market officially notified ...
2023-05-05 16:20:22 ET Mereo BioPharma ( NASDAQ: MREO ) said it had received approval to transfer listing of its ADS from Nasdaq Global Market to Nasdaq Capital Market. The transfer was effective at the opening of business on May 3, 2023. The Nasdaq Capital Market oper...
LONDON, May 05, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that it has received approval from Listing Qualifications Department of th...
LONDON, April 13, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, and other members...
2023-03-28 16:41:07 ET Mereo BioPharma Group press release ( NASDAQ: MREO ): FY GAAP EPS of -£0.06. As of December 31, 2022, the Company had cash and short-term deposits of £56.3 million Net loss attributable to equity holders for the year ended December 31, ...
LONDON, March 28, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the year ended December 31, 2022 and provided ...
2023-03-21 09:01:38 ET Investing in penny stocks can be highly rewarding, but it also comes with significant risks. The high-risk, high-reward nature of penny stocks means potential for significant returns. But they can also lose their entire investment if the stock’s price drops...
Clear path forward with proposed single Phase 3 study evaluating alvelestat at the 240 mg dose level versus placebo at 12-18 months for potential full approval in both the U.S. and EU No additional confirmatory study required Company to host conference call today at 8:30am ET LONDON...
Summary Mereo and Ultragenyx are collaborating to develop setrusumab, a sclerostin inhibitor, for treating patients with Osteogenesis Imperfecta. ASTEROID Phase 2 trial showed that setrusumab improved bone markers and density, and strength but not patient-reported outcomes or fracture r...
News, Short Squeeze, Breakout and More Instantly...
Mereo BioPharma Group Company Name:
MREO Stock Symbol:
NASDAQ Market:
Mereo BioPharma Group Website:
2024-06-20 09:00:06 ET Joseph Schwartz from Leerink Partners issued a price target of $8.00 for MREO on 2024-06-20 07:21:00. The adjusted price target was set to $8.00. At the time of the announcement, MREO was trading at $3.98. The overall price target consensus is at $...
2024-06-14 10:45:03 ET Cleanspark Inc (CLSK) CLSK is trading UP for the last 5 days, and it at trading at $18.30 with volume of 12,068,034 and a one day change of $0.33 (1.84%). Cleanspark Inc has a 52-week low of 3.38 and a 52-week high of $24.72. The business's 50-day moving avera...
LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the pricing of an underwritten offering of 12,531,300 of its American Dep...